Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naïve people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England.
Adult
Humans
Insulin
/ therapeutic use
Diabetes Mellitus, Type 2
/ drug therapy
Glycated Hemoglobin
Retrospective Studies
Glycemic Control
Treatment Outcome
Insulin, Isophane
/ adverse effects
Biphasic Insulins
/ adverse effects
Insulin Aspart
/ adverse effects
Hypoglycemic Agents
/ therapeutic use
Insulin, Regular, Human
Cohort Studies
England
/ epidemiology
cohort study
database research
insulin analogues
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
17
05
2023
received:
24
01
2023
accepted:
21
05
2023
medline:
3
8
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
This study investigated the ethnic differences in glycaemic levels and clinical characteristics among insulin-naïve people with type 2 diabetes (T2D) initiating biphasic insulin aspart 30/70 (BIAsp 30) in primary practice in England. Retrospective, observational cohort study utilizing data from the Clinical Practice Research Datalink Aurum database, including White, South Asian, Black and Chinese insulin-naïve adults with T2D, initiating BIAsp 30. The index date was that of the first BIAsp 30 prescription. Endpoints included change in glycated haemoglobin (HbA1c) and body mass index (BMI) 6 months post index. In total, 11 186 eligible people were selected (9443 White, 1116 South Asian, 594 Black, 33 Chinese). HbA1c decreased across all subgroups 6 months post index: estimated %-point changes [95% CI of -2.32 (-2.36; -2.28) (White); -1.91 (-2.02; -1.80) (South Asian); -2.55 (-2.69; -2.40) (Black); and -2.64 (-3.24; -2.04) (Chinese)]. The BMI increased modestly 6 months post index in all subgroups [estimated changes (95% CI) kg/m Among insulin-naïve people with T2D initiating BIAsp 30, clinically meaningful HbA1c reductions in all ethnicities were observed. Some ethnic groups had larger reductions than others, but differences were small. In all groups, small BMI increases were seen, with small differences observed between groups. Hypoglycaemia rates were low.
Substances chimiques
insulin aspart, insulin aspart protamine drug combination 30:70
0
Insulin
0
Glycated Hemoglobin
0
Insulin, Isophane
53027-39-7
Biphasic Insulins
0
Insulin Aspart
D933668QVX
Hypoglycemic Agents
0
Insulin, Regular, Human
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2756-2764Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes-2022. Diabetes Care. 2022;45:S125-S143.
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527-532.
Unnikrishnan R, Gupta PK, Mohan V. Diabetes in South Asians: phenotype, clinical presentation, and natural history. Curr Diab Rep. 2018;18:30.
Kibirige D, Lumu W, Jones AG, Smeeth L, Hattersley AT, Nyirenda MJ. Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clin Diabetes Endocrinol. 2019;5:2.
do Vale Moreira NC, Ceriello A, Basit A, et al. Race/ethnicity and challenges for optimal insulin therapy. Diabetes Res Clin Pract. 2021;175:108823.
Dickinson S, Colagiuri S, Faramus E, Petocz P, Brand-Miller JC. Postprandial hyperglycemia and insulin sensitivity differ among lean young adults of different ethnicities. J Nutr. 2002;132:2574-2579.
Novo Nordisk Limited. NovoMix® 30. Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/1600/smpc. Accessed 07 December 2022.
Liebl A, Mohan V, Yang W, Strojek K, Linjawi S. 15 years of experience with biphasic insulin aspart 30 in type 2 diabetes. Drugs R D. 2018;18:27-39.
Clinical Practice Research Datalink. CPRD Aurum April 2021 (Version 2021.04.001) [Data set]. 2021. doi:10.48329/8pm6-4q84
UK Government. List of ethnic groups. https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups. Accessed 07 December 2022.
Oyer DS, Shepherd MD, Coulter FC, et al. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med. 2009;122:1043-1049.
Trippe BS, Shepherd MD, Coulter FC, et al. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial). Curr Med Res Opin. 2012;28:1203-1211.
Ladwa M, Bello O, Hakim O, et al. Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men. BMJ Open Diabetes Res Care. 2021;9:e002034.
Mathur R, Farmer RE, Eastwood SV, Chaturvedi N, Douglas I, Smeeth L. Ethnic disparities in initiation and intensification of diabetes treatment in adults with type 2 diabetes in the UK, 1990-2017: a cohort study. PLoS Med. 2020;17:e1003106.
Zaccardi F, Tan PS, Coupland C, et al. Ethnicity and risks of severe COVID-19 outcomes associated with glucose-lowering medications: a cohort study. Diabetes Obes Metab. 2022;25:611-617.
Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485-502.
Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228-2234.
Maiorino MI, Chiodini P, Bellastella G, et al. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2019;154:101-115.
UK Government. Population of England and Wales 2018. https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/population-of-england-and-wales/latest. Accessed 24 August 2022.
Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health (Oxf). 2014;36:684-692.